Diuretic resistance risk and the efficacy of torsemide vs furosemide: a post-hoc analysis of the TRANSFORM-HF trial

Authors:

Abstract
Background/Aims: Among hospitalized patients with heart failure (HF), diuretic resistance is associated with residual congestion, poor health status, and increased risk of HF hospitalization and mortality in the post-discharge period. The TRANSFORM-HF trial demonstrated no significant difference between torsemide and furosemide on clinical outcomes or quality-of-life following HF hospitalization. We assessed the association between diuretic resistance risk, assessed using the BAN-ADHF score, with risk of adverse outcomes among participants of the TRANSFORM-HF trial, and whether diuretic resistance risk modified the treatment effects of torsemide vs furosemide. Methods: This post-hoc analysis of TRANSFORM-HF included participants randomized to torsemide or furosemide who survived to discharge with available BAN-ADHF scores. High diuretic resistance risk was defined as BAN-ADHF score ≥12 during index hospitalization. Associations of diuretic resistance risk with 12-month all-cause mortality, all-cause hospitalization, and quality of life (KCCQ-CSS) were assessed using adjusted Cox models, and linear mixed-effects models, respectively. Treatment effect modification was assessed via interaction terms between randomized treatment and diuretic resistance risk status (high vs low). Results: Among 2421 participants (age: 65 years, 62.9% male), 512 (21%) had high diuretic resistance risk. High diuretic resistance risk was independently associated with increased risk of all-cause mortality (aHR[95%CI]: 1.79[1.45–2.21], P < .001), all-cause hospitalization (aHR: 1.34[1.15–1.55], P < .001), and lower 12-month KCCQ-CSS improvement (−3.4 points, P = .037). Diuretic resistance risk status did not modify the treatment effect of torsemide vs furosemide on all-cause mortality (Pinteraction = .54), all-cause hospitalization (Pinteraction = .74), or quality-of-life on follow-up (Pinteraction > .05 at each timepoint). Conclusion: Among patients discharged after HF hospitalization, higher diuretic resistance risk, assessed by the BAN-ADHF score, is associated with higher risk of mortality, HF hospitalization, and worse quality-of-life. Diuretic resistance risk status did not modify the treatment effects of torsemide vs furosemide.

This publication has 25 references indexed in Scilit: